DESTINY-GASTRIC-01

NCT03329690 📎

Regimen

Experimental
trastuzumab deruxtecan (T-DXd) 6.4 mg/kg
Control
physician's choice chemotherapy

Population

Japanese/Korean HER2-positive advanced gastric/GEJ cancer progressing after >=2 lines including trastuzumab

Key finding

ORR 51% vs 14% (p<0.001); mOS 12.5 vs 8.4 mo (HR 0.59, 95% CI 0.39-0.88, p=0.01); ILD 9 grade 1-2, 3 grade 3-4

Source: PMID 32469182

Timeline

    Guideline citations

    • NCCN GASTRIC (p.102)
    • CSCO GASTRIC 2025 (p.96)⚠️ OCR source